Pholcodine
drug drugOn this page
Also known as BiocalyptolCodylinDEA NO. 9314Dia-tussEthnineEvapholEvaphol strongFolcodinaFolcodineGalenpholGlycodineGppe linctHibernylHomocodeineIDS-NP-011(SECT.2)MemineMorpholinylethylmorphineNeocodinePavacol-d
Summary
Pholcodine (CHEMBL2105224) is an approved small-molecule opioid analgesic (ATC R05DA08); indicated across 1 condition.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: R05DA08
- Indications: 1 condition
- Clinical trials: 1
- Chemistry: 398.5 Da · C23H30N2O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2105224 |
| Name | Pholcodine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 5311356 |
| ChEBI | CHEBI:53579 |
| ATC | R05DA08 |
| Molecular formula | C23H30N2O4 |
| Molecular weight | 398.5 |
| InChIKey | GPFAJKDEDBRFOS-FKQDBXSBSA-N |
SMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OCCN6CCOCC6)O[C@H]3[C@H](C=C4)O
IUPAC name: (4R,4aR,7S,7aR,12bS)-3-methyl-9-(2-morpholin-4-ylethoxy)-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
ChEBI definition: A morphinane alkaloid that is a derivative of morphine with a 2-morpholinoethyl group at the 3-position.
Pharmacological roles (ChEBI): antitussive, opioid analgesic, μ-opioid receptor agonist, drug allergen.
Also known as: Biocalyptol, Codylin, DEA NO. 9314, Dia-tuss, Ethnine, Evaphol, Evaphol strong, Folcodina, Folcodine, Galenphol, Glycodine, Gppe linct
Patent coverage: 799 distinct patent families (2,555 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05501288 | Not specified | COMPLETED | Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.